Relative contribution of SF3B1 mutation status to the ability of IPSS or WPSS to predict OS in MDS patients*
| Risk factor . | Hazard ratio . | P . |
|---|---|---|
| Multivariate analysis including IPSS | ||
| Age (< 70 y vs ≥ 70 y) | 1.52 | .224 |
| Sex (male vs female) | 0.69 | .292 |
| IPSS risk group | 2.16 | < .001 |
| SF3B1 mutation status (mutation present vs absent) | 0.21 | .038 |
| Multivariate analysis including WPSS | ||
| Age (< 70 y vs ≥ 70 y) | 1.39 | .324 |
| Sex (male vs female) | 0.86 | .668 |
| WPSS risk group | 1.96 | < .001 |
| SF3B1 mutation status (mutation present vs absent) | 0.23 | .050 |
| Risk factor . | Hazard ratio . | P . |
|---|---|---|
| Multivariate analysis including IPSS | ||
| Age (< 70 y vs ≥ 70 y) | 1.52 | .224 |
| Sex (male vs female) | 0.69 | .292 |
| IPSS risk group | 2.16 | < .001 |
| SF3B1 mutation status (mutation present vs absent) | 0.21 | .038 |
| Multivariate analysis including WPSS | ||
| Age (< 70 y vs ≥ 70 y) | 1.39 | .324 |
| Sex (male vs female) | 0.86 | .668 |
| WPSS risk group | 1.96 | < .001 |
| SF3B1 mutation status (mutation present vs absent) | 0.23 | .050 |
Multivariate analysis of OS was performed using a Cox proportional hazards regression model that included age, sex, IPSS risk group or WPSS risk group, and SF3B1 mutation status. IPSS and WPSS were modeled as a continuous covariate.